How do target of rapamycin inhibitors (TOR-I) compare with calcineurin inhibitors (CNI) for primary immunosuppression in kidney transplant recipients?

2020 ◽  
Author(s):  
Samira Bell
Keyword(s):  
Kidney Transplant ◽  
Calcineurin Inhibitors ◽  
Target Of Rapamycin ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

Immunosuppressive Management of Pediatric Kidney Transplant Recipients

2020 ◽  
Vol 26 (28) ◽  
pp. 3451-3459
Author(s):  
Tomáš Seeman
Keyword(s):  
Immunosuppressive Therapy ◽  
Kidney Transplant ◽  
Induction Therapy ◽  
Graft Loss ◽  
Calcineurin Inhibitors ◽  
Mtor Inhibitors ◽  
Therapeutic Drug ◽  
High Dose ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

: Kidney transplantation is a preferable treatment of children with end-stage kidney disease. All kidney transplant recipients, including pediatric need immunosuppressive medications to prevent rejection episodes and graft loss. : Induction therapy is used temporarily only immediately following transplantation while maintenance immunosuppressive drugs are started and given long-term. There is currently no consensus regarding the use of induction therapy in children; its use should be decided based on the immunological risk of the child. : The recent progress shows that the recommended strategy is to use as maintenance immunosuppressive therapy a combination of a calcineurin inhibitor (preferably tacrolimus) with an antiproliferative drug (preferably mycophenolate mofetil) with steroids that can be withdrawn early or late in low-risk children. The mTOR-inhibitors (sirolimus, everolimus) are used rarely in pediatrics because of common side effects and no evidence of a benefit over calcineurin inhibitors. The use of calcineurin inhibitors, mycophenolate, and mTOR-inhibitors should be followed by therapeutic drug monitoring. : Immunosuppressive therapy of acute rejection consists of high-dose steroids and/or anti-lymphocyte antibodies (T-cell mediated rejection) or plasma exchange, intravenous immunoglobulines and/or rituximab (antibodymediated rejection). : The future strategies for research are mainly precise characterisation of children needing induction therapy, more specific indications for mTOR-inhibitors and for the far future, the possibility to reach the immuno tolerance.

scholarly journals Mammalian Target of Rapamycin Inhibitor Dyslipidemia in Kidney Transplant Recipients

2008 ◽  
Vol 8 (7) ◽  
pp. 1384-1392 ◽  
Author(s):  
B. L. Kasiske ◽  
A. de Mattos ◽  
S. M. Flechner ◽  
L. Gallon ◽  
H.-U. Meier-Kriesche ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Mammalian Target Of Rapamycin ◽  
Target Of Rapamycin ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

scholarly journals SP821THE EFFECTS OF CALCINEURIN INHIBITORS ON SPERM DNA FRAGMENTATION IN MALE KIDNEY TRANSPLANT RECIPIENTS

2015 ◽  
Vol 30 (suppl_3) ◽  
pp. iii648-iii649
Author(s):  
Alparslan Ersoy ◽  
Hale Samli ◽  
Cuma Bulent Gul ◽  
Murat Samli ◽  
Sena Ardicli ◽  
...  
Keyword(s):  
Dna Fragmentation ◽  
Kidney Transplant ◽  
Calcineurin Inhibitors ◽  
Sperm Dna Fragmentation ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Sperm Dna
Sign in / Sign up

Export Citation Format

Share Document